DHMBA Nephroprotective Composition for Mitochondrial ROS Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nephroprotective agents do not effectively address the oxidative stress-induced damage to mitochondrial functions in renal proximal tubular cells, leading to increased ROS production, cytotoxicity, and impaired mitochondrial respiration.
Innovation Solution
A nephroprotective agent containing 3,5-dihydroxy-4-methoxybenzyl alcohol (DHMBA) is developed, which acts as a reduction promoter of intramitochondrial ROS, inhibitor of cytotoxicity, and activator of mitochondrial respiration, thereby enhancing cell viability and mitochondrial count, and promoting mitochondrial biosynthesis and ATP production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional nephroprotective agents are used, then general kidney protection is provided, but oxidative stress-induced mitochondrial damage is not effectively addressed
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of DHMBA to create DHMBA derivatives with enhanced nephroprotective activity. Specifically, the invention introduces various substituents at different positions of the DHMBA molecular structure to optimize its ability to scavenge ROS and protect mitochondrial function in renal proximal tubular cells, thereby addressing the limitation of conventional agents that do not effectively target oxidative stress-induced mitochondrial damage
Solution Approach 2:
The patent employs composite materials by combining DHMBA derivatives with other compounds or formulations to create synergistic nephroprotective agents. The invention develops composite formulations that integrate DHMBA derivatives with complementary substances to enhance overall protective effects against oxidative stress while maintaining mitochondrial function, thus overcoming the insufficiency of single-agent conventional therapies
2Power
If oxidative stress increases, then ATP production increases, but excessive ROS are produced as by-products
Solution Approach 1:
The patent applies the blessing in disguise principle by utilizing DHMBA derivatives to convert the harmful effect of ROS into a beneficial outcome. The derivatives specifically target and scavenge excessive ROS generated during ATP production in mitochondrial oxidative phosphorylation, transforming the harmful by-product into an opportunity for protective action. This approach maintains ATP production while eliminating the harmful ROS, thereby resolving the contradiction between energy generation and oxidative damage
Solution Approach 2:
The patent employs an intermediary mechanism by introducing DHMBA derivatives as mediators between mitochondrial ATP production and ROS generation. These derivatives act as intermediaries that intervene in the oxidative phosphorylation process to scavenge ROS without interfering with ATP synthesis, thus mediating the relationship between energy production and harmful by-product formation, and resolving the contradiction between maintaining power output and reducing harmful emissions
3Reliability
If mitochondrial functions are maintained to balance ROS production and removal, then nephroprotection is achieved, but existing agents do not specifically target mitochondrial ROS
Solution Approach 1:
The patent applies local quality by designing DHMBA derivatives with specific structural modifications that enable them to selectively target mitochondrial ROS rather than acting generally throughout the cell. The derivatives are engineered to accumulate in mitochondria and specifically scavenge ROS at the mitochondrial level, providing localized protection where it is most needed. This local targeting approach maintains the ROS balance specifically in mitochondria, thereby achieving nephroprotection by addressing the root cause of oxidative damage in renal proximal tubular cells
Solution Approach 2:
The patent employs DHMBA derivatives as intermediaries that specifically mediate between mitochondrial ROS production and cellular antioxidant defenses. These derivatives act as intermediaries that directly interact with mitochondrial ROS, converting them into harmless substances, and thereby maintaining the ROS balance at the mitochondrial level. This intermediary action provides targeted nephroprotection by addressing intramitochondrial ROS specifically, which conventional agents fail to do effectively
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
DHMBA effectively reduces ROS accumulation, inhibits mitochondrial fragmentation, and enhances mitochondrial respiration and ATP production, providing a robust nephroprotective effect in human renal proximal tubular cells under oxidative stress.
Implementation Method 1
DHMBA was demonstrated to be a substance that has both of the functions [direct antioxidant potential and indirect antioxidant potential]. Furthermore, DHMBA was found to be less cytotoxic than existing antioxidant substances.
Implementation Method 2
the activation of radical scavenging ability and the Keap1-Nrf2 pathway by DHMBA and associated expression induction of antioxidant gene clusters (such as HO-1 and NQO1) have been confirmed
Implementation Method 3
In mitochondria, using high-energy electrons and oxygen molecules, adenosine triphosphate (ATP) as a source of energy is synthesized
Implementation Method 4
Some of the mtDNA and its gene products are also localized on cell surfaces, and their mutations are specifically eliminated by the innate immune system
Data Source
AI summary
It is an objective of the present invention to provide respective useful agents that contain 3,5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient and have a nephroprotective useful action, such as a nephroprotective useful agent, by further conducting the development of the inventions of respective useful agents containing 3,5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient, which have already been acquired by the present inventors. The present invention is a nephroprotective useful agent including 3,5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient, the nephroprotective useful agent having a nephroprotective useful action.